The nomination states, “Dr. Schreiber provided us with some personal interaction during a time of government mandated social isolation and general ambiguity from the earliest stages of the pandemic.”
The CTNI, made possible by a $4.9 million grant from the Massachusetts Life Sciences Center, will improve brain imaging techniques and open doors to developing diagnostics and treatments for neurodegenerative diseases.
These findings further advance our understanding of CTE and lay the groundwork for diagnosis during life using brain imaging techniques that can identify the specific tau of CTE in the brains of living people.
Therapeutic manipulations of these cells hold promise for promoting muscle injury repair and improving outcomes for individuals with muscular dystrophy.